303 related articles for article (PubMed ID: 24914846)
1. [New biomarkers to optimize the selection and follow up of patients with prostate cancer on active surveillance].
López-Guerrero JA; Casanova-Salas I; Fernández-Serra A; Rubio L; Calatrava A; García-Flores M; García-Casado Z; Rubio-Briones J
Arch Esp Urol; 2014 Jun; 67(5):462-72. PubMed ID: 24914846
[TBL] [Abstract][Full Text] [Related]
2. [Optimization of follow up in prostate cancer active surveillance].
Celma Domènech A; Planas Morin J; Morote Robles J
Arch Esp Urol; 2014 Jun; 67(5):442-51. PubMed ID: 24914843
[TBL] [Abstract][Full Text] [Related]
3. Defining 'progression' and triggers for curative intervention during active surveillance.
Klotz L
Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
[TBL] [Abstract][Full Text] [Related]
4. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
5. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
7. What is the best way not to treat prostate cancer?
Leapman MS; Carroll PR
Urol Oncol; 2017 Feb; 35(2):42-50. PubMed ID: 27746147
[TBL] [Abstract][Full Text] [Related]
8. Role of the pathologist in active surveillance for prostate cancer.
Mazzucchelli R; Galosi AB; Santoni M; Lopez-Beltran A; Scarpelli M; Cheng L; Montironi R
Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):65-8. PubMed ID: 26072636
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
[TBL] [Abstract][Full Text] [Related]
11. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
12. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.
Trock BJ
Curr Opin Urol; 2014 May; 24(3):293-302. PubMed ID: 24710054
[TBL] [Abstract][Full Text] [Related]
13. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
15. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
16. Predicting high risk disease using serum and DNA biomarkers.
Vesprini D; Liu S; Nam R
Curr Opin Urol; 2013 May; 23(3):252-60. PubMed ID: 23449497
[TBL] [Abstract][Full Text] [Related]
17. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
18. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
19. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
20. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]